Over a light lunch, Steve will discuss Anatara's progress in commercialising innovative, evidence-based products for areas of gastrointestinal health where there is significant unmet need. The Company's lead program is focused on the development of a dietary supplement to fill a gap in currently available treatment options for sufferers of gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), which affects more than 20% of the Australian population.
Shareholder information session details are as follows:
Date: Tuesday 18th June 2019
Time: 12.30pm - 2.30pm Lunch will be provided
Venue: Australian Institute of Company Directors (AICD) Business Centre
Allendale Square, 1/77 St Georges Terrace, Perth, WA 6000
Please kindly register your attendance and any dietary requirements, by Wednesday 12th June 2019 to Hayley van der Meer at email@example.com.
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.